TY - JOUR T1 - Reversal of direct oral anticoagulants: Highlights from the Anticoagulation Forum guideline JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 98 LP - 103 DO - 10.3949/ccjm.88a.19133 VL - 88 IS - 2 AU - Haeshik S. Gorr AU - Lucy Yun Lu AU - Eric Hung Y1 - 2021/02/01 UR - http://www.ccjm.org/content/88/2/98.abstract N2 - The 2019 guideline from the Anticoagulation Forum provides clear instructions on how to use 2 agents for reversing the effects of direct oral anticoagulants (DOACs): idarucizumab for dabigatran-associated bleeding and andexanet alfa for bleeding associated with rivaroxaban and apixaban. The guideline also discusses off-label use of andexanet alfa for bleeding associated with edoxaban and betrixaban and the use of hemostatic agents such as activated prothrombin complex concentrate and 4-factor prothrombin complex concentrate. Lastly, it offers approaches for building and managing stewardship programs at the health system level. ER -